Komori
S

SUS Co.,Ltd.

6554Information and Communications, Services and OthersMicro cap
1,102JPY-1.2%
★ Watch (sign-up required)
Price history
¥1,102Latest+17.2%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A summary lands here once the filings have been read.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
11.03How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
2.06How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
18.7%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥10.0bnShare price × number of shares. The value of the entire company.
Equity ratio
59.9%The proportion of assets funded by money that does not have to be repaid.
Operating margin
9.6%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
12.6%The average annual growth in sales over the past three years.
What to watch next
Optimization of recruitment and deployment, including the opening of the Fukuoka office, becomes visible through higher utilization and increased orders
From 2026 onward, depending on the progress of office operations and personnel deploymentImpact MediumLikelihood Medium
Higher sophistication in management systems and decision-making through the use of generative AI is reflected in margin improvement through lower indirect costs and higher productivity
2026 onwardImpact MediumLikelihood Low
The conversion of AR/VR education and platforms to e-learning, along with updates to education programs, leads to customer acquisition and recurring subscriptions or orders
2026 onwardImpact MediumLikelihood Medium
The regenerative medicine business, including Prime Road's cell culture and processing facility, moves from preparation to concrete execution, including progress on capital investment plans and clarification of order and partnership terms
From 2026 onward, depending on the progress of the opening and capital investmentImpact HighLikelihood Low
What to watch next
Loading
Who owns itTop holders total 64.4%
Listed holders 64.4%Everyone else 35.6%
Saito Kimio (齋藤 公男)50.79%
セファテクノロジー株式会社4.93%
Oku Naohiko (奥 直彦)1.26%
加賀 章弘1.23%
大槻 哲也1.21%
小林 孝史1.09%
SBI Securities Co., Ltd.1.08%
STATE STREET BANK AND TRUST COMPANY 5051030.99%
2 other listed holders1.84%
Who owns it
HolderOwnership (%)
Saito Kimio (齋藤 公男)50.79
セファテクノロジー株式会社4.93
Oku Naohiko (奥 直彦)1.26
加賀 章弘1.23
大槻 哲也1.21
小林 孝史1.09
SBI Securities Co., Ltd.1.08
STATE STREET BANK AND TRUST COMPANY 5051030.99
2 other listed holders1.84
This company's documents
Filings
Timely disclosures
Threads